NCT02432144View on ClinicalTrials.gov

A Study of UX003 Recombinant Human Beta-Glucuronidase (rhGUS) Enzyme Replacement Therapy in Subjects With Mucopolysaccharidosis Type 7, Sly Syndrome (MPS 7)

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 10, 2015

Primary Completion Date

January 14, 2019

Study Completion Date

January 14, 2019

Conditions

Sly SyndromeMPS VIIMucopolysaccharidosisMucopolysaccharidosis VII

Interventions

DRUG

UX003

solution for intravenous (IV) infusion

Trial Locations (7)

20230

Centenario Hospital Miguel Hidalgo, Pediatrics, Aguascalientes

55455

University of Minnesota, Minneapolis

77030

Baylor College of Medicine, Houston

92868

Children's Hospital of Orange County, Orange

94609

Children's Hospital Oakland, Oakland

Unknown

Hospital Infantil Candido Fontoura Sao Paulo, São Paulo

4050-371

Unidade de Doenças Metabólicas - Centro Hospitalar do Porto, Porto

All Listed Sponsors

lead

Ultragenyx Pharmaceutical Inc

INDUSTRY

NCT02432144 - A Study of UX003 Recombinant Human Beta-Glucuronidase (rhGUS) Enzyme Replacement Therapy in Subjects With Mucopolysaccharidosis Type 7, Sly Syndrome (MPS 7) | Biotech Hunter | Biotech Hunter